NASDAQ:PRPH - ProPhase Labs Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $25.00
  • Forecasted Upside: 341.70 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.66
▲ +0.11 (1.98%)

This chart shows the closing price for PRPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ProPhase Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRPH

Analyst Price Target is $25.00
▲ +341.70% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ProPhase Labs in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 341.70% upside from the last price of $5.66.

This chart shows the closing price for PRPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in ProPhase Labs.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2021Dawson JamesDowngradeBuy ➝ NeutralMedium
1/20/2021Dawson JamesInitiated CoverageBuy$25.00High
(Data available from 10/20/2016 forward)

News Sentiment Rating

0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/20/2021

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Very Positive

  • No very positive mentions tracked during this time.
ProPhase Labs logo
ProPhase Labs, Inc. is a medical science and technology company. It engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The firm operates through the following business segments: Diagnostic Services and Consumer Products. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.
Read More

Today's Range

Now: $5.66
Low: $5.50
High: $5.88

50 Day Range

MA: $5.43
Low: $4.89
High: $7.67

52 Week Range

Now: $5.66
Low: $4.41
High: $16.04

Volume

53,252 shs

Average Volume

260,489 shs

Market Capitalization

$85.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ProPhase Labs?

The following equities research analysts have issued research reports on ProPhase Labs in the last twelve months: Dawson James, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for PRPH.

What is the current price target for ProPhase Labs?

1 Wall Street analysts have set twelve-month price targets for ProPhase Labs in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 341.7%. Dawson James has the highest price target set, predicting PRPH will reach $25.00 in the next twelve months. Dawson James has the lowest price target set, forecasting a price of $25.00 for ProPhase Labs in the next year.
View the latest price targets for PRPH.

What is the current consensus analyst rating for ProPhase Labs?

ProPhase Labs currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PRPH, but not buy more shares or sell existing shares.
View the latest ratings for PRPH.

How do I contact ProPhase Labs' investor relations team?

ProPhase Labs' physical mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The company's listed phone number is (215) 345-0919 and its investor relations email address is [email protected] The official website for ProPhase Labs is www.prophaselabs.com.